CXCL16 in kidney and cardiovascular injury

Cytokine and Growth Factor Reviews

Volumn 25, Issue 3, 2014, Pages 317-325

  Izquierdo, María Concepción ^a,b   Martin Cleary, Catalina ^a,b   Fernandez Fernandez, Beatriz ^a,b   Elewa, Usama ^a,b   Sanchez Niño, María D ^b,c   Carrero, Juan Jesús ^d   Ortiz, Alberto ^a,b,e  

^a 28400 Madrid   (Spain)

^b REDINREN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Atherosclerosis; Chemokine; Chronic kidney disease; Inflammation

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; ALPHA CHEMOKINE; CELL ADHESION MOLECULE; CXCL16 PROTEIN, HUMAN; SCAVENGER RECEPTOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CXCL16 GENE; DIABETIC NEPHROPATHY; DISEASE MARKER; GENE; GLYCOSYLATION; HEART INFARCTION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FIBROSIS; KIDNEY INJURY; MEMBRANOUS GLOMERULONEPHRITIS; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; ANIMAL; GENE EXPRESSION REGULATION; GLOMERULUS; KIDNEY DISEASE; METABOLISM; MORTALITY; PATHOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; CHEMOKINES, CXC; GENE EXPRESSION REGULATION; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; RECEPTORS, SCAVENGER;

EID: 84902079924     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.04.002     Document Type: Short Survey

References (89)

1. de Jager D.J., Grootendorst D.C., Jager K.J., van Dijk P.C., Tomas L.M., Ansell D., et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. J Am Med Assoc 2009, 302(October (16)):1782-1789.
2. Levey A.S., Beto J.A., Coronado B.E., Eknoyan G., Foley R.N., Kasiske B.L., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998, 32(November (5)):853-906.
3. Moreno J.A., Moreno S., Rubio-Navarro A., Sastre C., Blanco-Colio L.M., Gomez-Guerrero C., et al. Targeting chemokines in proteinuria-induced renal disease. Expert Opin Ther Targets 2012, 16(August (8)):833-845.
4. Gomez-Chiarri M., Ortiz A., Seron D., Gonzalez E., Egido J. The intercrine superfamily and renal disease. Kidney Int 1993, 39(January (Suppl.)):S81-S85.
5. Chung A.C., Lan H.Y. Chemokines in renal injury. J Am Soc Nephrol 2011, 22(May (5)):802-809.
6. Matloubian M., David A., Engel S., Ryan J.E., Cyster J.G. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000, 1(October (4)):298-304.
7. Shimaoka T., Kume N., Minami M., Hayashida K., Kataoka H., Kita T., et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000, 275(December (52)):40663-40666.
8. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385(February (6617)):640-644.
9. Pan Y., Lloyd C., Zhou H., Dolich S., Deeds J., Gonzalo J.A., et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997, 387(June (6633)):611-617.
10. Gough P.J., Garton K.J., Wille P.T., Rychlewski M., Dempsey P.J., Raines E.W. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004, 172(March (6)):3678-3685.
11. Schulte A., Schulz B., Andrzejewski M.G., Hundhausen C., Mletzko S., Achilles J., et al. Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases. Biochem Biophys Res Commun 2007, 358(June (1)):233-240.
12. Abel S., Hundhausen C., Mentlein R., Schulte A., Berkhout T.A., Broadway N., et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004, 172(May (10)):6362-6372.
13. Hundhausen C., Schulte A., Schulz B., Andrzejewski M.G., Schwarz N., von H.P., et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 2007, 178(June (12)):8064-8072.
14. Ludwig A., Schulte A., Schnack C., Hundhausen C., Reiss K., Brodway N., et al. Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J Neurochem 2005, 93(June (5)):1293-1303.
15. Ludwig A., Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost 2007, 97(May (5)):694-703.
16. Sanchez-Nino M.D., Ortiz A. Notch3 and kidney injury: never two without three. J Pathol 2012, 228(November (3)):266-273.
17. Sanchez-Nino M.D., Sanz A.B., Ruiz-Andres O., Poveda J., Izquierdo M.C., Selgas R., et al. MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple. Cytokine Growth Factor Rev 2013, 24(February (1)):23-40.
18. van d V., Verweij V., de Witte T.M., Lasonder E., Adema G.J., Dolstra H. An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells. J Leukoc Biol 2010, February.
19. Hofnagel O., Luechtenborg B., Plenz G., Robenek H. Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells. Arterioscler Thromb Vasc Biol 2002, 22(April (4)):710-711.
20. Dahl C.P., Husberg C., Gullestad L., Waehre A., Damas J.K., Vinge L.E., et al. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. Circ Heart Fail 2009, 2(November (6)):624-632.
21. Shashkin P., Simpson D., Mishin V., Chesnutt B., Ley K. Expression of CXCL16 in human T cells. Arterioscler Thromb Vasc Biol 2003, 23(January (1)):148-149.
22. Wilbanks A., Zondlo S.C., Murphy K., Mak S., Soler D., Langdon P., et al. Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001, 166(April (8)):5145-5154.
23. Schramme A., Abdel-Bakky M.S., Kampfer-Kolb N., Pfeilschifter J., Gutwein P. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells. Biochem Biophys Res Commun 2008, 370(May (2)):311-316.
24. Walker B., Towhid S.T., Schmid E., Hoffmann S.M., Abed M., Munzer P., et al. Dynamic adhesion of eryptotic erythrocytes to immobilized platelets via platelet phosphatidylserine receptors. Am J Physiol Cell Physiol 2013, November.
25. Schramme A., Abdel-Bakky M.S., Gutwein P., Obermuller N., Baer P.C., Hauser I.A., et al. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int 2008, 74(August (3)):328-338.
26. Gutwein P., Abdel-Bakky M.S., Schramme A., Doberstein K., Kampfer-Kolb N., Amann K., et al. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol 2009, 174(June (6)):2061-2072.
27. Izquierdo M.C., Sanz A.B., Mezzano S., Blanco J., Carrasco S., Sanchez-Nino M.D., et al. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int 2012, 81(June (11)):1098-1107.
28. Xia Y., Entman M.L., Wang Y. Critical role of CXCL16 in hypertensive kidney injury and fibrosis. Hypertension 2013, 62(December (6)):1129-1137.
29. Gutwein P., Abdel-Bakky M.S., Doberstein K., Schramme A., Beckmann J., Schaefer L., et al. CXCL16 and oxLDL are induced in the onset of diabetic nephropathy. J Cell Mol Med 2009, 13(September (9B)):3809-3825.
30. Gutwein P., Schramme A., Sinke N., Abdel-Bakky M.S., Voss B., Obermuller N., et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 2009, 45(February (3)):478-489.
31. Hojo S., Koizumi K., Tsuneyama K., Arita Y., Cui Z., Shinohara K., et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007, 67(May (10)):4725-4731.
32. Wagsater D., Hugander A., Dimberg J. Expression of CXCL16 in human rectal cancer. Int J Mol Med 2004, 14(July (1)):65-69.
33. Wente M.N., Gaida M.M., Mayer C., Michalski C.W., Haag N., Giese T., et al. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol 2008, 33(August (2)):297-308.
34. Lu Y., Wang J., Xu Y., Koch A.E., Cai Z., Chen X., et al. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res 2008, 6(April (4)):546-554.
35. Held-Feindt J., Rehmke B., Mentlein R., Hattermann K., Knerlich F., Hugo H.H., et al. Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes growth of human schwannomas. Glia 2008, 56(May (7)):764-774.
36. Oldham K.A., Parsonage G., Bhatt R.I., Wallace D.M., Deshmukh N., Chaudhri S., et al. T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur Urol 2012, 61(February (2)):385-394.
37. Chandrasekar B., Mummidi S., Valente A.J., Patel D.N., Bailey S.R., Freeman G.L., et al. The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 2005, 280(July (28)):26263-26277.
38. Zeng M., Yan H., Chen Y., Zhao H.J., Lv Y., Liu C., et al. Suppression of NF-kappaB reduces myocardial no-reflow. PLoS One 2012, 7(10):e47306.
39. Hofnagel O., Engel T., Severs N.J., Robenek H., Buers I. SR-PSOX at sites predisposed to atherosclerotic lesion formation mediates monocyte-endothelial cell adhesion. Atherosclerosis 2011, 217(August (2)):371-378.
40. Shimaoka T., Nakayama T., Fukumoto N., Kume N., Takahashi S., Yamaguchi J., et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 2004, 75(February (2)):267-274.
41. Borst O., Abed M., Alesutan I., Towhid S.T., Qadri S.M., Foller M., et al. Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012, 302(February (4)):C644-C651.
42. Abed M., Towhid S.T., Mia S., Pakladok T., Alesutan I., Borst O., et al. Sphingomyelinase-induced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol 2012, 303(November (9)):C991-C999.
43. Abed M., Towhid S.T., Feger M., Schmidt S., Kuro O., Gawaz M., et al. Adhesion of klotho-deficient eryptotic erythrocytes to endothelial cells. Acta Physiol (Oxf) 2013, 207(March (3)):485-493.
44. Abed M., Towhid S.T., Pakladok T., Alesutan I., Gotz F., Gulbins E., et al. Effect of bacterial peptidoglycan on erythrocyte death and adhesion to endothelial cells. Int J Med Microbiol 2013, 303(May (4)):182-189.
45. Wuttge D.M., Zhou X., Sheikine Y., Wagsater D., Stemme V., Hedin U., et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004, 24(April (4)):750-755.
46. Nakayama T., Hieshima K., Izawa D., Tatsumi Y., Kanamaru A., Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003, 170(February (3)):1136-1140.
47. Shimaoka T., Nakayama T., Kume N., Takahashi S., Yamaguchi J., Minami M., et al. Cutting edge: SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J Immunol 2003, 171(August (4)):1647-1651.
48. Kim C.H., Kunkel E.J., Boisvert J., Johnston B., Campbell J.J., Genovese M.C., et al. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest 2001, 107(March (5)):595-601.
49. Kim C.H., Johnston B., Butcher E.C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 2002, 100(July (1)):11-16.
50. Unutmaz D., Xiang W., Sunshine M.J., Campbell J., Butcher E., Littman D.R. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J Immunol 2000, 165(September (6)):3284-3292.
51. Huang Y., Zhu X.Y., Du M.R., Wu X., Wang M.Y., Li D.J. Chemokine CXCL16 a scavenger receptor, induces proliferation and invasion of first-trimester human trophoblast cells in an autocrine manner. Hum Reprod 2006, 21(April (4)):1083-1091.
52. Smith H., Whittall C., Weksler B., Middleton J. Chemokines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. Stem Cells Dev 2012, 21(February (3)):476-486.
53. Hara T., Katakai T., Lee J.H., Nambu Y., Nakajima-Nagata N., Gonda H., et al. A transmembrane chemokine, CXC chemokine ligand 16, expressed by lymph node fibroblastic reticular cells has the potential to regulate T cell migration and adhesion. Int Immunol 2006, 18(February (2)):301-311.
54. Hase K., Murakami T., Takatsu H., Shimaoka T., Iimura M., Hamura K., et al. The membrane-bound chemokine CXCL16 expressed on follicle-associated epithelium and M cells mediates lympho-epithelial interaction in GALT. J Immunol 2006, 176(January (1)):43-51.
55. van d V., van Lieshout A.W., Toonen L.W., Sloetjes A.W., van den Berg W.B., Figdor C.G., et al. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum 2005, 52(May (5)):1381-1391.
56. Sato T., Thorlacius H., Johnston B., Staton T.L., Xiang W., Littman D.R., et al. Role for CXCR6 in recruitment of activated CD8+ lymphocytes to inflamed liver. J Immunol 2005, 174(January (1)):277-283.
57. Boisvert J., Kunkel E.J., Campbell J.J., Keeffe E.B., Butcher E.C., Greenberg H.B. Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol 2003, 38(January (1)):67-75.
58. Heydtmann M., Lalor P.F., Eksteen J.A., Hubscher S.G., Briskin M., Adams D.H. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005, 174(January (2)):1055-1062.
59. Smith C., Halvorsen B., Otterdal K., Waehre T., Yndestad A., Fevang B., et al. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res 2008, 79(July (1)):195-203.
60. Chandrasekar B., Bysani S., Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem 2004, 279(January (5)):3188-3196.
61. Zhuge X., Murayama T., Arai H., Yamauchi R., Tanaka M., Shimaoka T., et al. CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. Biochem Biophys Res Commun 2005, 331(June (4)):1295-1300.
62. Sheikine Y., Sirsjo A. CXCL16/SR-PSOX-a friend or a foe in atherosclerosis?. Atherosclerosis 2008, 197(April (2)):487-495.
63. Borst O., Munzer P., Gatidis S., Schmidt E.M., Schonberger T., Schmid E., et al. The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling. Circ Res 2012, 111(October (10)):1297-1307.
64. Wu T., Xie C., Wang H.W., Zhou X.J., Schwartz N., Calixto S., et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007, 179(November (10)):7166-7175.
65. Wu T., Xie C., Bhaskarabhatla M., Yan M., Leone A., Chen S.S., et al. Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis Rheum 2007, 56(March (3)):949-959.
66. Teramoto K., Negoro N., Kitamoto K., Iwai T., Iwao H., Okamura M., et al. Microarray analysis of glomerular gene expression in murine lupus nephritis. J Pharmacol Sci 2008, 106(January (1)):56-67.
67. Garcia G.E., Truong L.D., Li P., Zhang P., Johnson R.J., Wilson C.B., et al. Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am J Pathol 2007, 170(May (5)):1485-1496.
68. Riedel J.H., Paust H.J., Turner J.E., Tittel A.P., Krebs C., Disteldorf E., et al. Immature renal dendritic cells recruit regulatory CXCR6(+) invariant natural killer T cells to attenuate crescentic GN. J Am Soc Nephrol 2012, 23(December (12)):1987-2000.
69. Okamura D.M., Lopez-Guisa J.M., Koelsch K., Collins S., Eddy A.A. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol 2007, 293(August (2)):F575-F585.
70. Chen G., Lin S.C., Chen J., He L., Dong F., Xu J., et al. CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. J Am Soc Nephrol 2011, 22(October (10)):1876-1886.
71. Xia Y., Entman M.L., Wang Y. CCR2 regulates the uptake of bone marrow-derived fibroblasts in renal fibrosis. PLoS One 2013, 8(10):e77493.
72. Wehr A., Baeck C., Heymann F., Niemietz P.M., Hammerich L., Martin C., et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol 2013, 190(May (10)):5226-5236.
73. Lin Z., Gong Q., Zhou Z., Zhang W., Liao S., Liu Y., et al. Increased plasma CXCL16 levels in patients with chronic kidney diseases. Eur J Clin Invest 2011, 41(August (8)):836-845.
74. Gong Q., Wu F., Pan X., Yu J., Li Y., Lu T., et al. Soluble C-X-C chemokine ligand 16 levels are increased in gout patients. Clin Biochem 2012, 45(November (16-17)):1368-1373.
75. Aslanian A.M., Charo I.F. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006, 114(August (6)):583-590.
76. Yi G.W., Zeng Q.T., Mao X.B., Cheng M., Yang X.F., Liu H.T., et al. Overexpression of CXCL16 promotes a vulnerable plaque phenotype in apolipoprotein E-Knockout Mice. Cytokine 2011, 53(March (3)):320-326.
77. Zhao G., Wang S., Wang Z., Sun A., Yang X., Qiu Z., et al. CXCR6 deficiency ameliorated myocardial ischemia/reperfusion injury by inhibiting infiltration of monocytes and IFN-gamma-dependent autophagy. Int J Cardiol 2013, 168(September (2)):853-862.
78. Minami M., Kume N., Shimaoka T., Kataoka H., Hayashida K., Akiyama Y., et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001, 21(November (11)):1796-1800.
79. Lehrke M., Millington S.C., Lefterova M., Cumaranatunge R.G., Szapary P., Wilensky R., et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007, 49(January (4)):442-449.
80. Sun Y., Chang Z., Zhang S. Increased serum CXCL16 level is a marker for acute coronary syndromes. Arch Med Res 2008, 39(April (3)):332-337.
81. Yang H.L., Xu Y.Y., Du L.F., Liu C.H., Zhao Q., Wei W.J., et al. Chemokine SR-PSOX/CXCL16 expression in peripheral blood of patients with acute coronary syndrome. Chin Med J (Engl) 2008, 121(January (2)):112-117.
82. Ueland T., Smedbakken L.M., Hallen J., Atar D., Januzzi J.L., Halvorsen B., et al. Soluble CXCL16 and long-term outcome in acute ischemic stroke. Atherosclerosis 2012, 220(January (1)):244-249.
83. Jansson A.M., Aukrust P., Ueland T., Smith C., Omland T., Hartford M., et al. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes. Circulation 2009, 119(June (25)):3181-3188.
84. Orn S., Breland U.M., Mollnes T.E., Manhenke C., Dickstein K., Aukrust P., et al. The chemokine network in relation to infarct size and left ventricular remodeling following acute myocardial infarction. Am J Cardiol 2009, 104(November (9)):1179-1183.
85. Jansson A.M., Hartford M., Omland T., Karlsson T., Lindmarker P., Herlitz J., et al. Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2012, 32(December (12)):3041-3049.
86. Sheikine Y., Bang C.S., Nilsson L., Samnegard A., Hamsten A., Jonasson L., et al. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis 2006, 188(October (2)):462-466.
87. Mitsuoka H., Toyohara M., Kume N., Hayashida K., Jinnai T., Tanaka M., et al. Circulating soluble SR-PSOX/CXCL16 as a biomarker for acute coronary syndrome -comparison with high-sensitivity C-reactive protein. J Atheroscler Thromb 2009, 16(October (5)):586-593.
88. Lv Y., Hou X., Ti Y., Bu P. Associations of CXCL16/CXCR6 with carotid atherosclerosis in patients with metabolic syndrome. Clin Nutr 2013, 32(October (5)):849-854.
89. Meijer J., Ogink J., Kreike B., Nuyten D., de Visser K.E., Roos E. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res 2008, 68(June (12)):4701-4708.